Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.

Abstract

24,25(OH)2D3 has been compared with 1,25(OH)2D3 in the treatment of renal osteodystrophy. Treatment with 24, 25(OH)2D3 2 micrograms/day for 5-7 months was accompanied by deterioration in clinical, biochemical, radiological and histological features of osteodystrophy with no increase in Ca absorption. In contrast, treatment with 1,25(OH)2D3 0.25--1 microgram/day for 6-15 months resulted in rapid improvement in clinical, biochemical, radiological and histological features and a return of Ca absorption to normal. It is concluded that in the dose used 24,25(OH)2D3 alone is not an effective treatment for renal osteodystrophy.

• Authors: N Muirhead, G R Catto, N Edward, R A Fraser, J L O'Riordan, S E Papapoulos, S Adami
• Journal: Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association (Proc Eur Dial Transplant Assoc) Vol. 17 Pg. 543-7 ( 1980) ISSN: 0071-2736 [Print] England
• PMID: 6972529 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Dihydroxycholecalciferols
• Hydroxycholecalciferols
• Phosphates
• 24,25-Dihydroxyvitamin D 3
• Alkaline Phosphatase
• Calcitriol
• Calcium

Topics

• 24,25-Dihydroxyvitamin D 3
• Adult
• Alkaline Phosphatase (blood)
• Calcitriol
• Calcium (blood)
• Chronic Kidney Disease-Mineral and Bone Disorder (blood, drug therapy)
• Dihydroxycholecalciferols (therapeutic use)
• Humans
• Hydroxycholecalciferols (therapeutic use)
• Middle Aged
• Phosphates (blood)